Profile: Seattle Genetics Inc (SGEN.O)
28 Apr 2017
Seattle Genetics, Inc., incorporated on July 15, 1997, is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC.
The Company's ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). ADCETRIS employs a linker system that is designed to be stable in the bloodstream and to release MMAE upon internalization into CD30-expressing cells. As of January 31, 2017, ADCETRIS was commercially available in 66 countries for relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). ADCETRIS has received approval for three indications: for the treatment of patients with classical Hodgkin lymphoma after failure of auto- Hematopoietic stem cell transplantation (HSCT); for the treatment of classical Hodgkin lymphoma patients at high risk of relapse or progression as post-auto-HSCT consolidation, and for the treatment of patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen. In the European Union ADCETRIS has been granted conditional marketing authorization for the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma following autologous stem cell transplantation (ASCT), and for the treatment of adult patients with relapsed or refractory sALCL.
ASG-22ME is an ADC composed of an anti-Nectin-4 monoclonal antibody linked to a potent auristatin compound using its ADC technology. Nectin-4 is a target expressed in multiple cancers, including urothelial cancers, such as bladder cancer, as well as ovarian and lung cancers. The Company is developing ASG-22ME as a potential treatment of solid tumors under its co-development collaboration with Astellas Pharma, Inc. (Astellas). As of December 31, 2016, he Company had completed the Phase I clinical trials for ASG-22ME.
SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody linked to a potent auristatin compound using its ADC technology, and is a product candidate for the treatment of LIV-1-positive metastatic breast cancer. As of December 31, 2016, the Company was focused on conducting a Phase I, open-label, dose-escalation clinical trial to evaluate the safety and antitumor activity of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer.
SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody linked to a potent auristatin compound using its ADC technology. CD19 is a B-cell antigen that is expressed in non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia (ALL). As of December 31, 2016, the Company was focused on initiation of a randomized Phase II clinical trial of SGN-CD19A in combination with the second-line salvage regimen of rituximab, ifosfamide, carboplatin and etoposide (RICE), for patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL).
SGN-CD19B is an ADC comprising an anti-CD19 monoclonal antibody utilizing its Eupergit C Monoclonal antibody (EC-mAb) technology linked to a potent pyrrolobenzodiazepine (PBD) dimer. The Company is developing this product candidate as a potential treatment of non-Hodgkin lymphoma. As of December 31, 2016, the Company was focused on conducting Phase I, open-label, multi-center, dose-escalation clinical trial of SGN-CD19B.
SGN-CD123A is an ADC composed of an anti-CD123 monoclonal antibody utilizing the EC-mAb technology linked to a potent PBD dimer. The Company is developing this product candidate as a potential treatment of acute myeloid leukemia (AML). As of December 31, 2016, the Company was focused on initiation of a Phase I, open-label, multi-center, dose-escalation clinical trial of SGN-CD123A for patients with relapsed or refractory AML.
ASG-15ME is an ADC composed of an anti-SLITRK6 monoclonal antibody linked to a potent auristatin compound using its ADC technology. The Company is developing ASG-15ME under its co-development collaboration with Astellas. The Company, together with Astellas, is focused on its development activities on ASG-22ME for metastatic urothelial cancer, while evaluating next development steps for ASG-15ME. As of December 31, 2016, ASG-15ME was in Phase I clinical trial.
SEA-CD40 utilizes the SEA technology to produce a non-fucosylated antibody targeting CD40. As of December 31, 2016, SEA-CD40 was in a Phase I trial in metastatic or unresectable solid tumors and hematologic malignancies.
SGN-2FF is a small molecule immuno-oncology agent. It is an oral agent that has been shown in preclinical models to inhibit fucosylation of proteins. As of January 2017, The Company had initiated an open-label, multi-center, dose-escalation clinical trial of SGN-2FF for patients with relapsed or refractory solid tumors, including non-small cell lung cancer.
The Company competes with Bristol-Myers Squibb Company, Celgene and Spectrum Pharmaceuticals.
Seattle Genetics Inc
21823 30th Dr SE
BOTHELL WA 98021-3907
Company Web Links
- BRIEF-Seattle Genetics Q1 loss per share $0.42
- BRIEF-Seattle Genetics' CEO Clay Siegall's 2016 total compensation $9.6 mln - SEC Filing
- BRIEF-Seattle Genetics presents data advancing antibody-drug conjugate at AACR annual meeting
- Seattle Genetics to resume trials as FDA lifts clinical hold
- UPDATE 1-Seattle Genetics to resume trials as FDA lifts clinical hold